Disparities in Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors prescription and dispensing in the Israeli population – a retrospective cohort study.

• DOI: 10.2337/figshare.25076096
• Publication Date: 2024-02-20T21:37:27Z
• Authors: Yaara Leibovici W...; Bronislava Calvar...; Tzippy Shochat; Zoya Korotkov; Alon Grossman; Leonard Leibovici; Adi Turjeman
• Keywords: 03 medical and health sciences; 0302 clinical medicine

<p dir="ltr">Objective: To describe disparities in prescribing and dispensing Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) Israel.</p><p dir="ltr">Research Design Methods: A population-based retrospective cohort study of adults with type 2 diabetes mellitus eligible for SGLT2i treatment from 2017 to 2023. The primary outcome was time between initial eligibility first prescription SGLT2i. </p><p dir="ltr">Results: Among 32,742 patients, only 53% were prescribed Multivariable analyses, adjusting death as competing risk, revealed delays associated older age, Arab or Bedouin ethnicity, neoplasms, acute kidney failure, falls, previous hospitalization, urinary tract infections dementia. Factors shorter intervals gender (men), medium/high socioeconomic status residing an intermediate central area dir="ltr">Conclusions: Disparities drug exist even a country universal health coverage. Addressing these requires improvements healthcare systems, education alert systems overcome barriers evidence-based interventions. </p>